Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial.
Hugo E VerdejoAdolfo RojasCamila López-CrisostoFernando BaraonaLuigi GabrielliVinicius Maracaja-CoutinhoMario ChiongSergio LavanderoPablo F CastroPublished in: Journal of clinical medicine (2023)
A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.
Keyphrases
- pulmonary artery
- clinical trial
- coronary artery
- end stage renal disease
- pulmonary hypertension
- pulmonary arterial hypertension
- blood pressure
- newly diagnosed
- chronic kidney disease
- mycobacterium tuberculosis
- ejection fraction
- heart failure
- peritoneal dialysis
- prognostic factors
- left ventricular
- randomized controlled trial
- emergency department
- adverse drug
- atrial fibrillation
- open label
- electronic health record
- phase ii
- polycyclic aromatic hydrocarbons